New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more: The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
via Google News
The Latest on: Glioblastoma
- GDC-0084 Shows Efficacy for Treatment of Glioblastomaon November 27, 2019 at 12:10 pm
GDC-0084, an investigational PI3K inhibitor, may delay the progression of disease in patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status, based on results of a phase IIa ...
- Exploring drug repurposing to treat glioblastomaon November 27, 2019 at 6:33 am
MALT1 blockers have long been in clinical use for the treatment of blood cancers. A study suggests that these drugs could potentially also be developed as a treatment option for glioblastoma, the most ...
- Tracking glioblastoma in central Illinoison November 26, 2019 at 3:33 pm
Glioblastoma is nearly always fatal, but it is difficult to get a handle on how many of our viewers are facing this threat. If you would like to share your current glioblastoma experience with us, you ...
- Australia’s Kazia Therapeutics reports positive interim results in phase II glioblastoma trialon November 26, 2019 at 3:18 pm
PERTH, Australia – Sydney-based Kazia Therapeutics Ltd.’s shares soared nearly 82% this week on positive interim results for lead molecule GDC-0084 in a phase II glioblastoma trial. Data from the ...
- Diffusion Pharmaceuticals' TSC: Thoughts On The Potential For Its Glioblastoma Indicationon November 26, 2019 at 3:22 am
Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke. The ...
- EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastomaon November 25, 2019 at 4:06 pm
Glioblastoma multiforme (GBM) represents 15-20% of all primary intracranial neoplasm, with death typically occurring within the first 15 months after diagnosis. The median age of diagnosis is 64 years ...
- Local man passes away after fight against glioblastomaon November 25, 2019 at 7:33 am
ST. LUCIE COUNTY, Fla. — His story helped bring needed attention to a deadly disease and bring hope to a community of people battling glioblastoma. This week, 35-year-old Mark Cunningham was laid to ...
- Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conferenceon November 24, 2019 at 3:18 pm
SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from ...
- Man loses fight against glioblastomaon November 22, 2019 at 8:30 pm
His story helped bring needed attention to a deadly disease and bring hope to a community of people battling glioblastoma. This week, 35-year-old Mark Cunningham was laid to rest after passing away ...
- Non-coding DNA located outside chromosomes may help drive glioblastomaon November 21, 2019 at 8:03 am
But it has remained unclear whether the additional DNA helps drive cancer or is just along for the ride. Using human glioblastoma brain tumor samples, researchers at University of California San Diego ...
via Bing News